Inhibition of HIV replication by sense and antisense Rev response elements in HIV-based retroviral vectors

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 4, 1996, Pages 343-351

  Kim, Jerome H ^a,b   McLinden, Robert J ^c   Mosca, Joseph D ^c   Vahey, Maryanne T ^b   Greene, Warner C ^d   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

Retroviral vectors; REV; Rev response element (RRE); TAT

Indexed keywords

STRUCTURAL PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; GENE EXPRESSION; GENE LOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETROVIRUS; TRANSACTIVATION; VIRUS EXPRESSION; VIRUS INDUCTION; VIRUS INHIBITION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0029811723     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199608010-00003     Document Type: Article

References (60)

1. Laspia MF, Rice AP, Mathews MB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989;59:283-92.
2. Southgate C, Zapp ML, Green MR. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. Nature 1990;345:640-2.
3. Bengal E, Aloni Y. Transcriptional elongation purified RNA polymerase II is blocked at the trans-activation responsive region of human immunodeficiency virus type 1 in vitro. J Virol 1991;65:4910-8.
4. Marciniak RA, Sharp PA. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J 1991;10:4189-96.
5. Feinberg MB, Jarrett RF, Aldovini A, Gallo RC, Wong SF. HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell 1986;46:807-17.
6. Sodroski J, Goh WC, Rosen C, Dayton A, Terwilliger E, Haseltine W. A second post-transcriptional trans-activator gene required for HTLV-III replication. Nature 1986;321: 412-7.
7. Fisher AG, Feinberg MB, Josephs SF, et al. The transactivation gene of HTLV-III is essential for virus replication. Nature 1986;320:367-71.
8. Rosen CA, Terwilliger E, Dayton A, Sodroski JG, Haseltine WA. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci USA 1988;85:2071-5.
9. Malim MH, Hauber J, Fenrick R, Cullen BR. Immunodeficiency virus Rev trans-activator modulates the expression of the viral regulatory genes. Nature 1988;335:181-3.
10. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989;338:254-7.
11. Malim MH, Böhnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant represser of Rev-function. Cell 1989;58:205-14.
12. Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, Cullen BR. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 1990;60:675-83.
13. Dayton AI, Terwilliger EF, Potz J, Kowalski M, Sodroski JG, Haseltine WA. Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus. J Acquir Immune Defic Syndr 1988;1:441-52.
14. Dayton ET, Powell DM, Dayton AI. Functional analysis of CAR, the target sequence for the Rev protein of HIV-1. Science 1989;246:1625-9.
15. Dayton ET, Konings DA, Powell DM, et al. Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein. J Virol 1992;66:1139-51.
16. Dayton ET, Konings DA, Lim SY, et al. The RRE of human immunodeficiency virus type 1 contributes to cell-type-specific viral tropism. J Virol 1993;67:2871-8.
17. Zapp ML, Green MR. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature 1989;342:714-6.
18. Zapp ML, Hope TJ, Parslow TG, Green MR. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci USA 1991;88: 7734-8.
19. Daly TJ, Cook KS, Gray GS, Maione TE, Rusche JR. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 1989;342:816-9.
20. Chang DD, Sharp PA. Regulation by HIV Rev depends upon recognition of splice sites. Cell 1989;59:789-95.
21. Cochrane AW, Chen CH, Rosen CA. Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA. Proc Natl Acad Sci USA 1990;87:1198-202.
22. Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992;66:150-9.
23. Nasiolas G, Zolotukhin AS, Tabernero C, et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 1994;68:2986-93.
24. Knight DM, Flomerfelt FA, Ghrayeb J. Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis. Science 1987;236:837-40.
25. Olsen HS, Nelbock P, Cochrane AW, Rosen CA. Secondary structure is the major determinant for interaction of HIV Rev protein with RNA. Science 1990;247:845-8.
26. Olsen HS, Beidas S, Dillon P, Rosen CA, Cochrane AW. Mutational analysis of the HIV-1 Rev protein and its target sequence, the Rev responsive element. J Acquir Immun Defic Syndr 1991;4:558-67.
27. Nalin CM, Purcell RD, Antelman D, et al. Purification and characterization of recombinant Rev protein of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1990; 87:7593-7.
28. Malim MH, Cullen BR. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991;65:241-8.
29. Malim MH, McCarn DF, Tiley LS, Cullen BR. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol 1991;65:4248-54.
30. Holland SM, Ahmad N, Maitra RK, Wingfield P, Venkatesan S. Human immunodeficiency virus Rev protein recognizes a target sequence in Rev-responsive element RNA within the context of RNA secondary structure. J Virol 1990;64:5966-75.
31. Dillon PJ, Nelbock P, Perkins A, Rosen CA. Function of the human immunodeficiency virus types 1 and 2 Rev proteins is dependent on their ability to interact with a structured region present in env gene mRNA. J Virol 1990;64:4428-31.
32. Arrigo SJ, Heaphy S, Haines JK. In vivo binding of wild-type and mutant human immunodeficiency virus type 1 Rev proteins: implications for function. J Virol 1992;66:5569-75.
33. Ahmed YF, Hanly SM, Malim MH, Cullen BR, Greene WC. Structure-function analysis of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev function. Genes Dev 1990;4:1014-22.
34. Solomin L, Felber BK, Pavlakis GN. Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1. J Virol 1990;64:6010-7.
35. Vaishnav YN, Vaishnav M, Wong-Staal F. Identification and characterization of a nuclear factor that specifically binds to the Rev response element (RRE) of human immunodeficiency virus type 1 (HIV-1). New Biol 1991;3:142-50.
36. Shukla RR, Kimmel PL, Kumar A. Human immunodeficiency virus type 1 Rev-responsive element RNA binds to host cell-specific proteins. J Virol 1994;68:2224-9.
37. Zimmermann K, Weber S, Dobrovnik M, Hauber J, Böhnlein E. Expression of chimeric neo-Rev response element sequences interferes with Rev-dependent HIV-1 gag expression. Hum Gene Ther 1992;3:155-61.
38. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990;63:601-8.
39. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991;65:6811-6.
40. Lisziewicz J, Sun D, Smythe J, et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene-therapy in AIDS. Proc Natl Acad Sci USA 1993;90:8000-4.
41. Rhodes A, James W. Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. J Gen Virol 1990;71:1965-74.
42. Hanly SM, Rimsky LT, Malim MH, et al. Comparative analysis of the HTLV-1 Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev 1989; 3:1534-44.
43. Rimsky L, Due Dodon M, Dixon EP, Greene WC. Trans-dominant inactivation of HTLV-1 and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator. Nature 1989;341:453-6.
44. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313:277-84.
45. Kim JH, Mosca JD, Vahey MT, McLinden RJ, Burke DS, Redfield RR. Consequences of human immunodeficiency virus type 1 superinfection of chronically infected cells. AIDS Res Hum Retroviruses 1993;9:875-82.
46. Takayama KM, Inouye M. Antisense RNA. Crit Rev Biochem Mol Biol 1990;25:155-84.
47. Stout JT, Caskey CT. Antisense RNA inhibition of endogenous genes. Methods Enzymol 1987;151:519-30.
48. Michael NL, Vahey MT, d'Arcy L, et al. Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. J Virol 1994;68:979-87.
49. Sczakiel G, Pawlita M. Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol 1991;65:468-71.
50. Meyer J, Nick S, Stamminger T, Grummt F, Jahn G, Lipps HJ. Inhibition of HIV-1 replication by a high-copy-number vector expressing antisense RNA for reverse transcriptase. Gene 1993;129:263-8.
51. Lo KM, Biasolo MA, Dehni G, Palu G, Haseltine WA. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 1992;190:176-83.
52. Sczakiel G, Oppenlander M, Rittner K, Pawlita M. Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol 1992;5576-81.
53. Rossi JJ, Elkins D, Zaia JA, Sullivan S. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. Aids Res Hum Retroviruses 1992;8:183-9.
54. Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 1992;4:66-74.
55. Richardson JH, Child LA, Lever AML. Packaging of human immunodeficiency virus type 1 RNA requires cis-acting sequences outside the 5′ leader region. J Virol 1993;67:3997-4005.
56. Lever AML, Gottlinger H, Haseltine W, Sodroski J. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 1989;63:4085-7.
57. + cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest 1991;88:1043-7.
58. Poznansky M, Lever AM, Bergeron L, Haseltine W, Sodroski J. Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol 1991;65:532-6.
59. Carroll R, Lin J-T, Dacquel EJ, Mosca JD, Burke DS, St. Louis DC. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J Virol 1994;68:6047-51.
60. Buchschacher GL, Panganiban AT. Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol 1992;66:2731-9.